Introduction: The prevalence of obesity worldwide has seen a steady upward trend in recent years. The prevalence of obesity is also increasing among the inflammatory bowel disease (IBD) population. A number of studies have shown that microRNAs are involved in both the regulation of inflammation and the control of the components that make up the metabolic syndrome, such as cholesterol, fatty acids, and their metabolism.
Aim: The aim of the present study was to investigate the relationship between BMI in patients with Crohn’s disease (CD) and the serum levels of some circulating microRNAs.
Materials and Methods: A total of 35 consecutive Crohn's disease patients (20 active and 15 in remission) and 30 healthy controls were tested for serum expression on a panel of 15 microRNAs. All had their BMI calculated.
Results: In the current study, the expression of miR-16_2, miR -28_1, miR -29c_1, miR -96_1 and miR -142-3p_2 was found to correlate positively with overweight and obesity in CD patients, while the expression of miR -144_4 and miR -1228-3p_1 correlated with normal body weight.
Conclusion: Contradictory results from the literature and the present study indicate that to establish and validate the expression pattern of the microRNAs in question, it is necessary to conduct large cohort studies with comparative results between patients with IBD and varying degrees of obesity, and healthy overweight controls.
Al-Rawaf. НА. Circulating microRNAs and adipokines as markers of metabolic syndrome in adolescents with obesity. Clinical Nutrition. Volume 38, Issue 5, October 2019, Pages 2231-2238
Blain A, Cattan S, Beaugerie L, et al. Crohn’s disease clinical course and severity in obese patients. Clin Nutr 2002; 21:51–57
Cabiati М., Randazzo Е., Salvadori C. Peroni D., Federico G., Del Ry S. Circulating microRNAs associated with C-type natriuretic peptide in childhood obesity. Peptides. Volume 133, November 2020, 170387, https://doi.org/10.1016/j.peptides.2020.170387
Chan SS, Luben R, Olsen A, et al. Body mass index and the risk for Crohn’s disease and ulcerative colitis: data from a European Prospective Cohort Study (The IBD in EPIC Study). Am J Gastroenterol 2013; 108:575–582
Chen C-Z, Schaffert S, Fragoso R, et al. Regulation of immune responses and tolerance: the microRNA perspective. Immunol Rev 2013;253:112–28
Erhayiem B, Dhingsa R, Hawkey CJ, Subramanian V. Ratio of visceral to subcutaneous fat area is a biomarker of complicated Crohn’s disease. Clin Gastroenterol Hepatol 2011; 9:684–687
Harper JW, Zisman TL. Interaction of obesity and inflammatory bowel disease. World J Gastroenterol 2016; 22:7868–7881
He A, Zhu L, Gupta N, Chang Y, Fang F. Overexpression of micro ribonucleic acid 29, highly upregulated in diabetic rats, leads to insulin resistance in 3T3-L1 adipocytes. Mol Endocrinol. 2007;21:2785–94
Kalla R, Ventham NT, Kennedy NA, et al. Gut 2014;0:1–14. doi:10.1136/gutjnl-2014-307891
Karkeni E, et al. Obesity-associated inflammation induces microRNA-155 expression in adipocytes and adipose tissue: outcome on adipocyte function. J. Clin. Endocrinol. Metab. 2016;101(4):1615e26
Khalili H, Ananthakrishnan AN, Konijeti GG, et al. Measures of obesity and risk of Crohn’s disease and ulcerative colitis. Inflamm Bowel Dis 2015; 21:361–368
Kim NH, Ahn J, Choi YM, Son HJ, Choi WH, Cho HJ, Yu JH, Seo JA, Jang YJ, Jung CH, Ha TY. Differential circulating and visceral fat microRNA expression of non-obese and obese subjects. Clin Nutr. 2020 Mar;39(3):910-916. doi: 10.1016/j.clnu.2019.03.033
Kim S, Pak Y. Caveolin-2 regulation of the cell cycle in response to insulin in Hirc-B fibroblast cells. Biochem Biophys Res Commun. 2005; 330:88–96
Kluiver J, et al. BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. J. Pathol. 2005;207(2):243e9
Li Y, Zhu W, Gong J, et al. Visceral fat area is associated with a high risk for early postoperative recurrence in Crohn’s disease. Colorectal Dis 2015; 17:225–234
Mattiske S, et al. The oncogenic role of miR-155 in breast cancer. Cancer Epidemiol. Prev. Biomark 2012;21(8):1236e43
Miura, N. et al. Serum messenger RNAas a biomarkerand its clinical usefulness in malignancies. Clin. Med. Insights Oncol. 2008, 2, 511–527
Moran GW, Dubeau MF, Kaplan GG, et al. The increasing weight of Crohn’s disease subjects in clinical trials: a hypothesis-generatings time-trend analysis. Inflamm Bowel Dis 2013; 19:2949–2956
O’Connell RM, et al. Inositol phosphatase SHIP1 is a primary target of miR-155. Proc. Natl. Acad. Sci. USA 2009;106(17):7113e8
O’Connell RM, et al. MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development. Immunity 2010;33(4):607e19
O'Neill S, Bohl M, Gregersen S, Hermansen K, O'Driscoll L. Blood-Based Biomarkers for Metabolic Syndrome. Trends Endocrinol Metab. 2016 Jun;27(6):363-374. doi: 10.1016/j.tem.2016.03.012
Pandey AK, et al. miR-29a levels are elevated in the db/db mice liver and its overexpression leads to attenuation of insulin action on PEPCK gene expression in HepG2 cells. Mol Cell Endocrinol. 2011; 332:125–33
Pullen TJ, da Silva Xavier G, Kelsey G, Rutter GA. miR-29a and miR-29b contribute to pancreatic beta-cell-specific silencing of monocarboxylate transporter 1 (Mct1). Mol Cell Biol. 2011; 31:3182–94
Rottiers, V., Naar,A.M. MicroRNAs in metabolism and metabolic disorders. Nat. Rev.Mol.CellBiol. 2012, 13, 239–250
Seminerio JL, Koutroubakis IE, Ramos-Rivers C, et al. Impact of obesity on the management and clinical course of patients with inflammatory bowel disease. Inflamm Bowel Dis 2015; 21:2857–2863
WHO Global Health Observatory Data Repository [online database]. Geneva, World Health Organization, 2013 (http://apps.who.int/gho/data/view.main, accessed 21 May 2013)
Xiao C, Rajewsky K. MicroRNA control in the immune system: basic principles. Cell 2009;136:26–36
https://www.euro.who.int/en/health-topics/noncommunicable-diseases/obesity/data-and-statistics
